ARTICLE | Clinical News
Exelon Patch rivastigmine regulatory update
July 25, 2011 7:00 AM UTC
Novartis disclosed in its 2Q11 earnings that Japan's Ministry of Health, Labor and Welfare (MHLW) approved Exelon Patch rivastigmine to treat mild to moderate Alzheimer's disease. The pharma also disc...